Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review

Annalisa Perna, Arrigo Schieppati, Javier Zamora, Giovanni A. Giuliano, Norbert Braun, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Background: This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN). Methods: We reviewed randomized controlled trials (RCTs) addressing the effect of immunosuppression on histologically proven IMN in adults with nephrotic syndrome followed up for at least 6 months. The literature was searched according to Cochrane Collaboration guidelines. Four therapeutic classes were considered: (1) steroids (alone), (2) alkylating agents (alone or in combination with steroids), (3) calcineurin inhibitors (alone or in combination with steroids), and (4) antiproliferative agents (alone). Results: Eighteen RCTs were selected (1,025 patients). Overall, no differences were found between immunosuppressive treatment and placebo or no treatment. For oral glucocorticoid therapy, no beneficial effect was observed. For alkylating agents, a beneficial effect was observed on complete remission (relative risk [RR], 2.37; 95% confidence interval [CI], 1.32 to 4.25; P = 0.004). Excluding patients with particularly well-preserved renal function, there was no significant difference in complete remission. Cyclophosphamide therapy resulted in a lower rate of adverse-event discontinuations compared with chlorambucil (8 versus 21 discontinuations, respectively; RR, 2.34; 95% CI, 1.25 to 4.39; P = 0.008). For calcineurin inhibitors, no difference was observed. For antiproliferative agents, a paucity of data did not allow a conclusion. Conclusion: The meta-analysis failed to show a long-term effect of treatment on patient and/or renal survival. There is weak evidence that the immunosuppressive regimen increased the remission rate. The review of safety showed a higher number of discontinuations for adverse events in immunosuppressive-treatment groups and that cyclophosphamide had fewer side effects than chlorambucil.

Original languageEnglish
Pages (from-to)385-401
Number of pages17
JournalAmerican Journal of Kidney Diseases
Volume44
Issue number3
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Membranous Glomerulonephritis
Immunosuppressive Agents
Chlorambucil
Alkylating Agents
Steroids
Therapeutics
Cyclophosphamide
Immunosuppression
Randomized Controlled Trials
Confidence Intervals
Kidney
Nephrotic Syndrome
Glucocorticoids
Meta-Analysis
Placebos
Guidelines
Safety

Keywords

  • adult
  • Idiopathic membranous nephropathy (IMN)
  • immunosuppressive therapy
  • nephrotic syndrome (NS)
  • systematic review

ASJC Scopus subject areas

  • Nephrology

Cite this

Immunosuppressive treatment for idiopathic membranous nephropathy : A systematic review. / Perna, Annalisa; Schieppati, Arrigo; Zamora, Javier; Giuliano, Giovanni A.; Braun, Norbert; Remuzzi, Giuseppe.

In: American Journal of Kidney Diseases, Vol. 44, No. 3, 09.2004, p. 385-401.

Research output: Contribution to journalArticle

Perna, Annalisa ; Schieppati, Arrigo ; Zamora, Javier ; Giuliano, Giovanni A. ; Braun, Norbert ; Remuzzi, Giuseppe. / Immunosuppressive treatment for idiopathic membranous nephropathy : A systematic review. In: American Journal of Kidney Diseases. 2004 ; Vol. 44, No. 3. pp. 385-401.
@article{56f9db2da74b47d9a8526aabebf94cde,
title = "Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review",
abstract = "Background: This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN). Methods: We reviewed randomized controlled trials (RCTs) addressing the effect of immunosuppression on histologically proven IMN in adults with nephrotic syndrome followed up for at least 6 months. The literature was searched according to Cochrane Collaboration guidelines. Four therapeutic classes were considered: (1) steroids (alone), (2) alkylating agents (alone or in combination with steroids), (3) calcineurin inhibitors (alone or in combination with steroids), and (4) antiproliferative agents (alone). Results: Eighteen RCTs were selected (1,025 patients). Overall, no differences were found between immunosuppressive treatment and placebo or no treatment. For oral glucocorticoid therapy, no beneficial effect was observed. For alkylating agents, a beneficial effect was observed on complete remission (relative risk [RR], 2.37; 95{\%} confidence interval [CI], 1.32 to 4.25; P = 0.004). Excluding patients with particularly well-preserved renal function, there was no significant difference in complete remission. Cyclophosphamide therapy resulted in a lower rate of adverse-event discontinuations compared with chlorambucil (8 versus 21 discontinuations, respectively; RR, 2.34; 95{\%} CI, 1.25 to 4.39; P = 0.008). For calcineurin inhibitors, no difference was observed. For antiproliferative agents, a paucity of data did not allow a conclusion. Conclusion: The meta-analysis failed to show a long-term effect of treatment on patient and/or renal survival. There is weak evidence that the immunosuppressive regimen increased the remission rate. The review of safety showed a higher number of discontinuations for adverse events in immunosuppressive-treatment groups and that cyclophosphamide had fewer side effects than chlorambucil.",
keywords = "adult, Idiopathic membranous nephropathy (IMN), immunosuppressive therapy, nephrotic syndrome (NS), systematic review",
author = "Annalisa Perna and Arrigo Schieppati and Javier Zamora and Giuliano, {Giovanni A.} and Norbert Braun and Giuseppe Remuzzi",
year = "2004",
month = "9",
doi = "10.1053/j.ajkd.2004.05.020",
language = "English",
volume = "44",
pages = "385--401",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunosuppressive treatment for idiopathic membranous nephropathy

T2 - A systematic review

AU - Perna, Annalisa

AU - Schieppati, Arrigo

AU - Zamora, Javier

AU - Giuliano, Giovanni A.

AU - Braun, Norbert

AU - Remuzzi, Giuseppe

PY - 2004/9

Y1 - 2004/9

N2 - Background: This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN). Methods: We reviewed randomized controlled trials (RCTs) addressing the effect of immunosuppression on histologically proven IMN in adults with nephrotic syndrome followed up for at least 6 months. The literature was searched according to Cochrane Collaboration guidelines. Four therapeutic classes were considered: (1) steroids (alone), (2) alkylating agents (alone or in combination with steroids), (3) calcineurin inhibitors (alone or in combination with steroids), and (4) antiproliferative agents (alone). Results: Eighteen RCTs were selected (1,025 patients). Overall, no differences were found between immunosuppressive treatment and placebo or no treatment. For oral glucocorticoid therapy, no beneficial effect was observed. For alkylating agents, a beneficial effect was observed on complete remission (relative risk [RR], 2.37; 95% confidence interval [CI], 1.32 to 4.25; P = 0.004). Excluding patients with particularly well-preserved renal function, there was no significant difference in complete remission. Cyclophosphamide therapy resulted in a lower rate of adverse-event discontinuations compared with chlorambucil (8 versus 21 discontinuations, respectively; RR, 2.34; 95% CI, 1.25 to 4.39; P = 0.008). For calcineurin inhibitors, no difference was observed. For antiproliferative agents, a paucity of data did not allow a conclusion. Conclusion: The meta-analysis failed to show a long-term effect of treatment on patient and/or renal survival. There is weak evidence that the immunosuppressive regimen increased the remission rate. The review of safety showed a higher number of discontinuations for adverse events in immunosuppressive-treatment groups and that cyclophosphamide had fewer side effects than chlorambucil.

AB - Background: This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN). Methods: We reviewed randomized controlled trials (RCTs) addressing the effect of immunosuppression on histologically proven IMN in adults with nephrotic syndrome followed up for at least 6 months. The literature was searched according to Cochrane Collaboration guidelines. Four therapeutic classes were considered: (1) steroids (alone), (2) alkylating agents (alone or in combination with steroids), (3) calcineurin inhibitors (alone or in combination with steroids), and (4) antiproliferative agents (alone). Results: Eighteen RCTs were selected (1,025 patients). Overall, no differences were found between immunosuppressive treatment and placebo or no treatment. For oral glucocorticoid therapy, no beneficial effect was observed. For alkylating agents, a beneficial effect was observed on complete remission (relative risk [RR], 2.37; 95% confidence interval [CI], 1.32 to 4.25; P = 0.004). Excluding patients with particularly well-preserved renal function, there was no significant difference in complete remission. Cyclophosphamide therapy resulted in a lower rate of adverse-event discontinuations compared with chlorambucil (8 versus 21 discontinuations, respectively; RR, 2.34; 95% CI, 1.25 to 4.39; P = 0.008). For calcineurin inhibitors, no difference was observed. For antiproliferative agents, a paucity of data did not allow a conclusion. Conclusion: The meta-analysis failed to show a long-term effect of treatment on patient and/or renal survival. There is weak evidence that the immunosuppressive regimen increased the remission rate. The review of safety showed a higher number of discontinuations for adverse events in immunosuppressive-treatment groups and that cyclophosphamide had fewer side effects than chlorambucil.

KW - adult

KW - Idiopathic membranous nephropathy (IMN)

KW - immunosuppressive therapy

KW - nephrotic syndrome (NS)

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=4444235009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444235009&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2004.05.020

DO - 10.1053/j.ajkd.2004.05.020

M3 - Article

C2 - 15332211

AN - SCOPUS:4444235009

VL - 44

SP - 385

EP - 401

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -